GIOTRIF in First Line Therapy of Advanced NSCLC With EGFR-mutations

Launched by BOEHRINGER INGELHEIM · Jan 27, 2014

Keywords

ClinConnect Summary

Study Design:

Gender

ALL

Eligibility criteria

• Inclusion criteria:
• • EGFR- tyrosine kinase inhibitor (TKI) naive patients with histologically confirmed locally advanced or metastatic NSCLC with activating EGFR-mutations
• • Age \>= 18 years
• • No diagnostic or therapeutic measures beyond routine clinical practice are required
• • Patients for whom the treating physician has decided to initiate treatment with GIOTRIF
• • Written informed consent prior inclusion
• Exclusion criteria:
• • Contraindication for Afatinib according to the Summary of Product characteristics
• • Participation in another clinical study until 30 days after end of treatment
• • Prior systemic chemotherapy (Neo-/adjuvant therapy is permitted)
• • Previous treatment with an EGFR-tyrosine kinase inhibitor
• • Patients not willing or not able to fill in quality of life questionnaires
• • Patients with missing or impaired legal capacity
• • Pregnancy